Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Video Expert Opinion
Colleague Insights
Living Resources
Conferences
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Advanced Melanoma

Journal Scan / Research · February 14, 2022

Neoadjuvant Targeted Therapy for Borderline Resectable Late-Stage BRAF V600 Positive Melanoma

Cancers

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Viola Franke MD

Cancers
Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma
Cancers (Basel) 2021 Dec 27;[EPub Ahead of Print], AM Czarnecka, K Ostaszewski, A Borkowska, A Szumera-Ciećkiewicz, K Kozak, T Świtaj, P Rogala, I Kalinowska, H Koseła-Paterczyk, K Zaborowski, P Teterycz, A Tysarowski, D Makuła, P Rutkowski

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated